Key Takeaways
OS Therapies (NYSE American: OSTX) will host a conference call on April 30 to present pivotal biomarker data for its cancer therapy, OST-HER2, supporting a planned U.S. regulatory filing in H2 2026.
The company announced the call will review data for its OST-HER2 Immune Signature, a pharmacodynamic biomarker it proposes as a surrogate endpoint to gain accelerated market access, according to a corporate filing. The call is scheduled for 8:30 AM ET on April 30, 2026.
The clinical-stage oncology company is pursuing a Biologics License Application (BLA) under the FDA's Accelerated Approval Program for its lead asset in osteosarcoma. OST-HER2 has already received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the U.S. regulator, and similar designations from the European Medicines Agency.
A successful BLA under the Rare Pediatric Disease Designation would make OS Therapies eligible for a Priority Review Voucher (PRV), which it intends to sell. The company highlighted a recent PRV transaction in February 2026 that was valued at $205 million.
Beyond the U.S., OS Therapies is also seeking Conditional Marketing Authorisations in Europe, the United Kingdom, and Australia. The company noted it has several regulatory meetings remaining in the second quarter of 2026, including two with the U.S. FDA and one with the U.K.'s MHRA. Follow-up meetings with the EU's EMA and Australia's TGA are also planned.
The upcoming data presentation and subsequent regulatory discussions represent a critical step in de-risking the company's lead asset. Investors will be closely watching the outcome of the Q2 meetings ahead of the planned BLA submission in the second half of the year.
This article is for informational purposes only and does not constitute investment advice.
